MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. M

MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. David I. Bruce, President and CEO of Iridex, shared: "The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward mu

MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effective, March 17, 2022. In connection with Ms. Huss' appointment to the board, the size of the board was increased from five to six members as of the Effective Date. "I am very pleased to welcome Beverly to our board of directors," said Scott Shuda, chairman of the board of Iridex. "Beverly's extensive management and board experience in the medical device industry and proven track record with non-invasive a

MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 for domestic callers or +1-646-968-2525 for interna

MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. M

MOUNTAIN VIEW, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended June 29, 2024, and provided a business update. Second Quarter 2024 Financial and Recent Highlights Generated total revenue of $12.6 million, representing sequential growth of 7% from the first quarter of 2024Cyclo G6® product family revenue was $3.3 million, representing sequential growth of 13% from the first quarter of 2024 Sold 15,100 Cyclo G6 probes, compared to

MOUNTAIN VIEW, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- IRIDEX Corporation ("Iridex", or the "Company") (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced it has executed definitive agreements related to a private placement financing (the "Financing") of a senior convertible promissory note (the "Initial Note") with Lind Global Asset Management IX LLC, an entity managed by The Lind Partners (together, "Lind"), which will result in net proceeds of approximately $3.5 million at closing. Subject to certain conditions, the Company may issue

MOUNTAIN VIEW, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter 2024 and provide a business update after the close of trading on Thursday, August 8, 2024. The Company's management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (646) 307-1963 for domestic callers or (800) 715-9871 for international cal

MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 30, 2024, and provided a business update. First Quarter 2024 Financial Highlights Generated total revenue of $11.8 million, compared to $13.7 million in the prior year periodCyclo G6® product family revenue in the first quarter of $3.0 million, compared to $3.7 million in the prior year period Sold 13,300 Cyclo G6 probes, compared to 12,700 in the prior quarter a

MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter 2024 after the close of trading on Tuesday, May 14, 2024. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the "Event Calendar" page of the "Investors" section of the Company

MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 30, 2023, and provided a business update. Fourth Quarter 2023 Results & Recent Highlights Generated total revenue of $12.5 million, compared to $15.2 million in the prior year periodCyclo G6® product family revenue in the fourth quarter of $3.0 million, compared to $4.2 million in the prior year period Sold 12,700 Cyclo G6 probes, co

MOUNTAIN VIEW, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced it will release financial results for the fourth quarter and full year 2023 and provide an update on its strategic review process after the close of trading on Tuesday, March 26, 2024. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the

MOUNTAIN VIEW, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the grant of the European Patent EP 3009093, entitled "Laser System with Short Pulse Characteristics and its Methods of Use". This groundbreaking patent further protects Iridex's intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments. Iridex is the exclusive provider of MicroPulse® devices that utilize the patented tech

8-K - IRIDEX CORP (0001006045) (Filer)

424B3 - IRIDEX CORP (0001006045) (Filer)

EFFECT - IRIDEX CORP (0001006045) (Filer)

8-K - IRIDEX CORP (0001006045) (Filer)

S-3 - IRIDEX CORP (0001006045) (Filer)

10-Q - IRIDEX CORP (0001006045) (Filer)

8-K - IRIDEX CORP (0001006045) (Filer)

8-K - IRIDEX CORP (0001006045) (Filer)

8-K - IRIDEX CORP (0001006045) (Filer)

SD - IRIDEX CORP (0001006045) (Filer)

Stifel analyst Thomas Stephan maintains Iridex (NASDAQ:IRIX) with a Hold and maintains $2 price target.

Gainers Arcutis Biotherapeutics (NASDAQ:ARQT) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1 earnings came out today. BioAtla (NASDAQ:BCAB) stock rose 13.02% to $2.95. The market value of their outstanding shares is at $141.9 million. As per the news, the Q1 earnings report came out today. OptimizeRx (NASDAQ:OPRX) stock increased by 7.55% to $11.25. The company's market cap stands at $204.5 million. As per the news, the Q1 earnings report came out today. Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 6.74% to $0.93. The market value of their outstanding shares is at $12.4 m

Iridex (NASDAQ:IRIX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.12) by 75 percent. This is a 61.54 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $11.76 million which missed the analyst consensus estimate of $12.00 million by 1.99 percent. This is a 14.19 percent decrease over sales of $13.71 million the same period last year.

Gainers Apollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. Cara Therapeutics (NASDAQ:CARA) shares moved upwards by 7.36% to $0.78. The company's market cap stands at $42.8 million. Coeptis Therapeutics (NASDAQ:COEP) shares moved upwards by 6.66% to $0.32. The company's market cap stands at $10.9 million. Titan Pharma (NASDAQ:TTNP) shares rose 6.44% to $7.75. The market value of their outstanding shares is at $5.8 million. BioSig Technologies (NASDAQ:BSGM) shares increased by 6.38% to $0.5. The market value of their outstanding shares is at $4.6 million. Iridex (NASDAQ:IRIX) stock in

Iridex (NASDAQ:IRIX) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Iridex missed estimated earnings by -260.0%, reporting an EPS of $-0.18 versus an estimate of $-0.05. Revenue was down $2.74 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.01 which was followed by a 7.000000000000001% increase in the share price the next day. Here's a look at Iridex's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.12 -0.11 -0.12 -0.11 EPS Actual -0.11 -0.17 -0.13 -0.07 Revenue Estimate 13.48M 14.23M 13.64M 15.16M Re

Iridex (NASDAQ:IRIX) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.05) by 260 percent. The company reported quarterly sales of $12.458 million which missed the analyst consensus estimate of $14.900 million by 16.39 percent. This is a 18.01 percent decrease over sales of $15.195 million the same period last year.

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. • AIM ImmunoTech (AMEX:AIM) is estimated to report earnings for its fourth quarter. • Elbit Systems (NASDAQ:ESLT) is projected to report quarterly earnings at $1.38 per share on revenue of $1.52 billion. • GDS Holdings (NASDAQ:GDS) is likely to report quarterly loss at $0.33 per share on revenue of $357.63 million. • Bragg Gaming Group (NASDAQ:BRAG) is estimated to report quarterly loss at $0.01 per share on revenue of $37.82 million. • BioLine Rx (NASDAQ:BLRX) is expected to report earnings for its fourth quarter. • Zhihu (NYSE:ZH) is li